glp-1 mlm GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GLP-1 receptor agonists | How

The formulation acts at multiple regulatory nodes along the gut-pancreas-peripheral tissue axis, simultaneously boosting hormone secretion and improving cellular glucose utilization

Although experimental studies suggest potential pancreatic harm from GLP-1 RAs, robust clinical evidence demonstrates that these drugs do not increase the incidence of pancreatitis or pancreatic cancer in diverse human populations

The semaglutide diet plan and tirzepatide diet plan both address this in detail

Patients taking GLP-1s may lose weight, improve glucose control, reduce cardiometabolic risk, and engage more intensively with health care